Natural history of hepatitis C virus infection;Historia natural de la infección por el VHC

Anales del Sistema Sanitario de Navarra

Volumn 27, Issue SUPPL. 2, 2004, Pages 51-58

  Uriz, J ^a   Briz, R ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

Cirrhosis; Fibrosis; Hepatitis C virus; Hepatocarcinoma; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 4; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; IMMUNOGLOBULIN; LAMININ; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ALCOHOL CONSUMPTION; CHRONIC HEPATITIS; DISEASE COURSE; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; REVIEW; SUPERINFECTION;

CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 4544228805     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. SEEFF LB. Natural history of hepatitis C. Hepatology 1997; 26 (Suppl 1): S21-27.
2. SEEFF LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl1): S35-37.
3. MARCELLIN P, ASSELAH T, BOYER N. Fibrosis and disease progresion in hepatitis C. Hepatology 2002; 36(Suppl.1): S47-56.
4. POYNARD T, RATZIU V, CHARLOTTE F, GOODMAN Z, MCHUTCHISON J, ALBRECHT J. Rates and risk factors for liver fibrosis progresion in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
5. MARCELLIN P, AKRÉMI R, CAZALS D, BOYER N, AUPERIN A, VIDAUD D et al. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis C. J Hepatol 2001; 34 (Suppl 1): 159 A.
6. GHANY MG, KLEINER DE, ALTER H, DOO E, KHOKAR F, PROMRAT K et al. Progresion of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
7. ALBERTI A, NOVENTA A, BENVEGNU L, BOCCATO S, GATTA A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis c virus infection. Ann Intern Med 2002; 137: 961-964.
8. SEEFF LB. The natural history of hepatitis C. A quandary. Hepatology 1998; 28: 1710-1711.
9. Kenny-Walsh E for Irish Hepatology Research Group. Clinical outcome after hepatitis C infection from contaminated andti-D immune globulin. N Engl J Med 1999; 340: 1228-1233.
10. WIESE M, BERR F, LAFRENZ M, PORST H, OLSEN V. Low frequency of cirrhosis in hepatitis C (genotipe 1b) single-source outbreak in Germany: a 20 year multicenter study. Hepatology 2000; 32: 91-96.
11. SEEFF LB, BUSKELL-BALES Z, WRIGHT EC, DURAKO SJ, ALTER HJ, IBER FL et al. Long-term mortality and morbidity of transfusión-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911.
12. SEEFF LB, HOLLINGER FB, ALTER HJ, WRIGHT EC, CAIN CM, BUSKELL-BALES Z et al. Long-term mortality and morbidity of transfussión-associated non-A, non-B and type C hepati-tis; a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-463.
13. FATTOVICH G, GISUTINA G, DEGOS F, TREMOLADA F, DIODATI G, ALMASIO P et al. Morbidity and mortality of compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
14. POYNARD T. Hepatitis C: somber views of natural history and optimistic views of interferon treatment. Hepatology 1998; 27: 1443-1444.
15. DI BISCEGLIE AM. Natural history of hepatitis C: Its Impact on Clinical Mangement. Hepatology 2000; 31: 1014-1018.